Epidermolysis bullosa: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• CD19 0

24 of 119 institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NIAMS · R21

  Modeling KRT5-linked skin disease to define key pathogenic drivers and novel therapeutic strategies

  University of Washington· Seattle, United States· US$401,807 awarded in fiscal year 2026· until Aug 2028

• NIH NIA · F31

  Characterizing concordance in the secretome of recessive dystrophic epidermolysis bullosa and cellular senescence

  University of Colorado Denver· Aurora, United States· US$37,938 awarded in fiscal year 2026· until Aug 2028

• NIH NIAMS · R01

  Chromatin Dynamics During Epithelial Commitment

  Stanford University· Stanford, United States· US$568,537 awarded in fiscal year 2026· until Jun 2029

• NIH NIDCR · R00

  Ameloblast-specific mineral ribbon attachment/elongation complex in enamel formation

  University of Michigan at Ann Arbor· Ann Arbor, United States· US$249,000 awarded in fiscal year 2026· until Jun 2027

• NIH NIAMS · R01

  The role of collagen VII in extracellular matrix protein secretion

  University of Wisconsin-Madison· Madison, United States· US$310,069 awarded in fiscal year 2026· until May 2029

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-DN

  Targeting Extracellular Matrix Remodelling in Cutaneous Wounds to Promote Better Healing (REMOD-HEALING)

  Centre National de la Recherche Scientifique Cnrs· Paris, France· EU contribution €3,620,987· until Oct 2029· 9 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon 2020) · ERC-ADG

  Custom-designed gene editing of induced epidermal stem cells for gene therapy of genetic diseases of squamous epithelia (Holo-GT)

  Universita Degli Studi di Modena e Reggio Emilia· Modena, Italy· EU contribution €2,462,375· until Aug 2027

7 of 12 running projects, newest first. Listed amounts together: US$2.5m + €6.1m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Suspended

  A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Disease

  NCT04031469· ProgenaBiome· Updated 21 Sept 2026

  “Administrative”Registry text, quoted unchanged. Source

• Withdrawn

  A Pilot Study to Explore the Role of Gut Flora in Epidermolysis Bullosa

  NCT04213703· ProgenaBiome· Updated 5 Jun 2025

  “Company shifted focus”Registry text, quoted unchanged. Source

• Terminated

  Open-label, Pivotal Clinical Trial to Confirm Efficacy and Safety of Autologous Grafts Containing Stem Cells Genetically Modified for Epidermis Restoration in Patients With Junctional Epidermolysis Bullosa

  NCT05111600· Holostem s.r.l.· Updated 19 Feb 2025

  “Development program review and update due to Sponsor re-organization”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• A Study to Learn About the Safety and Efficacy of the Drug Oleogel-S10 in Japanese Patients With Epidermolysis Bullosa

  NCT06917690· Chiesi Farmaceutici S.p.A.· Source

• A Pilot Study to Evaluate a Temporary Skin Substitute (Spincare® Matrix) for Wound Healing in RDEB Patients

  NCT05944250· Stanford University· Source

• Safety and efficacy of allogenic adipose tissue-derived mesenchymal stromal cells in patients with epidermolysis bullosa: Clinical trial phase I/II

  2024-516614-37-00· Masarykova Univerzita· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• CRISPR-Cas Systems 3
• Gene Expression Profiling 1
• Whole Genome Sequencing 1
• Exome Sequencing 4
• Proteomics 2
• Xenograft Model Antitumor Assays 1

See which targets of this disease your abstract mentions, and go to the people working on them.